{"id":"https://openalex.org/W3011071920","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.3061","title":"Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models.","display_name":"Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models.","alternate_titles":[],"publication_year":2013,"publication_date":"2013-05-20","ids":{"openalex":"https://openalex.org/W3011071920","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.3061","mag":"3011071920"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2013.31.15_suppl.3061","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.3061","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2013.31.15_suppl.3061","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W3011071920"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5025216625","display_name":"Mark Selby","orcid":"https://orcid.org/0000-0003-4421-6770","observed_orcids":["https://orcid.org/0000-0003-4421-6770"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Mark Selby","raw_affiliation_strings":["Bristol-Myers Squibb, Redwood City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Redwood City, CA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056978075","display_name":"John Engelhardt","orcid":"https://orcid.org/0009-0009-5205-4581","observed_orcids":["https://orcid.org/0009-0009-5205-4581"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"John Engelhardt","raw_affiliation_strings":["Bristol-Myers Squibb, Redwood City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Redwood City, CA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100804600","display_name":"Lisheng L\u00fc","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Li-Sheng Lu","raw_affiliation_strings":["Bristol-Myers Squibb, Redwood City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Redwood City, CA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109141030","display_name":"Michael M. Quigley","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Michael Quigley","raw_affiliation_strings":["Bristol-Myers Squibb, Redwood City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Redwood City, CA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100624273","display_name":"Changyu Wang","orcid":"https://orcid.org/0000-0002-3583-1379","observed_orcids":["https://orcid.org/0000-0002-3583-1379"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Changyu Wang","raw_affiliation_strings":["Bristol-Myers Squibb, Redwood City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Redwood City, CA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064202722","display_name":"Bingliang Chen","orcid":"https://orcid.org/0009-0008-0757-7722","observed_orcids":["https://orcid.org/0009-0008-0757-7722"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Bingliang Chen","raw_affiliation_strings":["Bristol-Myers Squibb, Redwood City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Redwood City, CA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5036054479","display_name":"Alan J. Korman","orcid":"https://orcid.org/0000-0002-1142-8542","observed_orcids":["https://orcid.org/0000-0002-1142-8542"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Alan J. Korman","raw_affiliation_strings":["Bristol-Myers Squibb, Redwood City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Redwood City, CA","institution_ids":["https://openalex.org/I4210091812"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210091812"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":80,"reviewed_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"31","issue":"15_suppl","first_page":"3061","last_page":"3061"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ctla-4-blockade","display_name":"CTLA-4 blockade","score":0.9259999990463257},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.7670000195503235},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.8650000095367432},{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":1.0},{"id":"https://openalex.org/keywords/pd-1","display_name":"PD-1","score":0.703000009059906},{"id":"https://openalex.org/keywords/ctla-4","display_name":"CTLA-4","score":0.9710000157356262},{"id":"https://openalex.org/keywords/pd-l1","display_name":"PD-L1","score":0.7680000066757202},{"id":"https://openalex.org/keywords/cd8-t-cell-infiltration","display_name":"CD8+ T cell infiltration","score":0.8659999966621399},{"id":"https://openalex.org/keywords/regulatory-t-cells","display_name":"regulatory T cells","score":0.9639999866485596},{"id":"https://openalex.org/keywords/gastrointestinal-toxicity","display_name":"gastrointestinal toxicity","score":0.6570000052452087},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.7559999823570251},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.8519999980926514},{"id":"https://openalex.org/keywords/synergistic-antitumor-effect","display_name":"synergistic antitumor effect","score":0.7080000042915344}],"concepts":[{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.8400784134864807},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.7551276683807373},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.649960994720459},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5839391946792603},{"id":"https://openalex.org/C167672396","wikidata":"https://www.wikidata.org/wiki/Q417800","display_name":"CD8","level":3,"score":0.5807210206985474},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.5650015473365784},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.5294173359870911},{"id":"https://openalex.org/C2778468042","wikidata":"https://www.wikidata.org/wiki/Q273976","display_name":"Blockade","level":3,"score":0.5075358152389526},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.4314875602722168},{"id":"https://openalex.org/C2781053074","wikidata":"https://www.wikidata.org/wiki/Q21100639","display_name":"PD-L1","level":4,"score":0.4308660924434662},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.4175838828086853},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.40133076906204224},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3922547698020935},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.30549395084381104},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.21937114000320435},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.18459591269493103},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.17170003056526184},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.09182009100914001},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.08015456795692444}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2013.31.15_suppl.3061","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.3061","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2013.31.15_suppl.3061","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2516271598","https://openalex.org/W4301174330","https://openalex.org/W2952065098","https://openalex.org/W2598942678","https://openalex.org/W4372342026","https://openalex.org/W2754718069","https://openalex.org/W2602291171","https://openalex.org/W3124047768","https://openalex.org/W7212161602","https://openalex.org/W2140521865"],"abstract_inverted_index":{"3061":[0],"Background:":[1],"Interaction":[2],"of":[3,46,60,65,82,89,93,104,119,152,160,166,176,213,221,227,273,298],"immune":[4],"checkpoint":[5],"molecules":[6],"PD-1":[7,22,228],"and":[8,10,51,68,95,179,191,224,257,294],"CTLA-4":[9,30],"their":[11],"respective":[12],"ligands":[13],"attenuates":[14],"antitumor":[15,134,168,289],"T":[16,86,173,189,194,207,231],"cell":[17,87,174,208,222],"responses.":[18],"In":[19,233],"clinical":[20,302],"studies,":[21],"blocking":[23,31],"antibody":[24],"(Ab)":[25],"nivolumab":[26,106,237,256,275],"(BMS-936558)":[27],"or":[28],"the":[29,44,161,265,296,299],"Ab":[32,154],"ipilimumab":[33,108,239,277],"result":[34,202],"in":[35,38,54,73,111,132,164,203,206,218,229,241,251,278,287,291,301],"durable":[36],"responses":[37],"multiple":[39],"human":[40],"malignancies.":[41],"We":[42],"describe":[43],"evaluation":[45,297],"concurrent":[47,83,105,148,198,236],"treatment":[48,61,84,118,185,199,283],"with":[49,62,122,138,255,259,284],"anti-PD-1":[50,66],"anti-CTLA-4":[52,69],"mAbs":[53],"preclinical":[55,101,262,292],"models.":[56],"Methods:":[57],"Antitumor":[58],"activity":[59,135,290],"murine":[63,76],"homologs":[64],"(4H2-mIgG1)":[67],"(9D9-mIgG2b)":[70],"was":[71,109,141],"evaluated":[72],"MC38,":[74],"a":[75,112,157,268],"colon":[77],"adenocarcinoma":[78],"model.":[79,115],"The":[80,100],"effects":[81],"on":[85],"infiltration":[88,175],"tumors,":[90],"tumoral":[91],"expression":[92,212],"PD-L1":[94,182],"cytokine":[96],"levels":[97,226],"were":[98],"explored.":[99],"safety":[102],"profile":[103],"+":[107,124,238,276],"assessed":[110],"cynomolgus":[113,234,253],"macaque":[114],"Results:":[116],"Concurrent":[117,282],"MC38":[120,177],"tumors":[121,178],"4H2-mIgG1":[123],"9D9-mIgG2b":[125],"(10":[126],"mg/kg":[127],"Q3d":[128],"x":[129],"3)":[130],"results":[131],"synergistic":[133,288],"whereas":[136],"efficacy":[137],"sequential":[139],"dosing":[140],"similar":[142],"to":[143,156],"either":[144],"agent":[145],"alone.":[146],"With":[147],"treatment,":[149],"dose":[150,159,269],"reductions":[151],"one":[153],"relative":[155],"fixed":[158],"other":[162],"resulted":[163,217,240,286],"retention":[165],"some":[167],"activity.":[169],"Anti-PD-1":[170,216],"enhanced":[171],"CD8+":[172,188,230],"increased":[180,186,211],"tumor":[181],"expression.":[183],"Anti-CTLA-4":[184],"intratumoral":[187,193,214],"cells":[190],"reduced":[192],"regulatory":[195],"cells.":[196,232],"While":[197],"did":[200],"not":[201,249],"further":[204],"increases":[205],"infiltration,":[209],"it":[210],"cytokines.":[215],"down":[219],"regulation":[220],"surface":[223],"intracellular":[225],"macaques,":[235],"dose-dependent":[242],"gastrointestinal":[243],"toxicities":[244],"(diarrhea;":[245],"body":[246],"weight":[247],"loss)":[248],"observed":[250],"earlier":[252],"studies":[254],"rarely":[258],"ipilimumab.":[260],"These":[261],"observations":[263],"provided":[264],"rationale":[266],"for":[267],"escalation":[270],"trial":[271],"(NCT01024231)":[272],"combined":[274],"advanced":[279],"melanoma.":[280],"Conclusions:":[281],"anti-PD-1/anti-CTLA-4":[285],"models":[293],"supports":[295],"combination":[300],"studies.":[303]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W3011071920","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":7},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":8},{"year":2017,"cited_by_count":6},{"year":2016,"cited_by_count":10},{"year":2015,"cited_by_count":11},{"year":2014,"cited_by_count":12},{"year":2013,"cited_by_count":5}],"updated_date":"2026-11-22T12:46:00.618207","created_date":"2020-03-23T00:00:00"}
